FDA Grants Priority Review to Astellas’ New Drug Application for Gilteritinib
Astellas Pharma announced today that the U.S. Food and Drug Administration (FDA) has accepted, with Priority Review, the company's New Drug Application (NDA) for gilteritinib for the…
Read More...
Read More...
